Abbott and Neurocrine Biosciences have entered into a collaboration to develop and commercialize elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that has recently completed a Phase ...

Elagolix is being developed by AbbVie and Neurocrine Biosciences, from whom the big pharma player in-licensed the drug in 2010 for $575 million. The oral treatment is also being developed as a ...